Grifols Stock (GRF): Price, the Takeover Overhang and Board Talking Points

Grifols, S.A. is a Spanish healthcare company — one of the global "big three" in plasma-derived medicines (immunoglobulin, albumin, clotting factors) plus diagnostics. Its Class A ordinary (voting) shares trade on the BME under GRF, with Class B non-voting preferred shares under GRF.P and a NASDAQ ADR under GRFS. Grifols is a member of the IBEX 35 (unchanged at the June 2026 review). A collapsed take-private approach, a short-seller controversy and a deleveraging story keep it heavily discussed in Spanish investor forums (foros de accionistas).

Price context

This page does not offer a price target. The fundamentals shareholders reference: for financial year 2025 (reported 26 February 2026) Grifols posted revenue of €7,524m (+7.0% at constant currency), adjusted EBITDA of €1,825m and group profit of €402m (+156%). In the first quarter of 2026, revenue was €1.7bn (+3.3% cc) with profit of €73m (+21.9%) and net leverage of 4.3x. First-half 2026 figures are due on 28 July 2026 and are not yet available. For a live quote, check your broker or the BME feed.

Board talking points — what investors are discussing

1. The take-private overhang. In July 2024 the founding family (with Brookfield) approached the company about taking it private; the board terminated those talks on 27 November 2024, having rejected the implied offer of about €10.50 per Class A share as undervaluing (that ~€10.50 figure is the board's own characterization). On 2 April 2025 the family vehicles confirmed "very preliminary" renewed talks — but there has been no firm bid since, so any current take-private should be treated as speculative. Whether an offer returns, and at what premium, is the single most-discussed thread.

2. The Class B discount. The persistent discount of the Class B shares (GRF.P / GRFS) to the Class A line is a recurring topic for holders.

3. The Gotham controversy — contested, not established. On 9 January 2024 short-seller Gotham City published a report alleging EBITDA overstatement and debt understatement via the consolidation of Scranton. These allegations are contested and have not been established as fact. On 24 July 2025 the CNMV resolved the matter with total fines of €1.356m — €800k to Grifols (over inaccurate 2021–23 consolidated data), €200k (misleading alternative-performance-measure disclosure) and about €356k across executives and family members (including CEO Nacho Abia). Importantly, the regulator faulted disclosure and presentation — it did not validate Gotham's fraud thesis, and it separately opened a market-manipulation probe into Gotham. Litigation continues: in the Grifols v. Gotham suit (SDNY), a 2025 ruling allowed one defamation claim to proceed (over an alleged undisclosed ~$95m Scranton loan).

4. The deleveraging glide. Investors weigh the credibility of leverage falling from 4.6x (FY24) to 4.2x (FY25) and 4.3x (Q1'26), now that all 2027 maturities have been refinanced and the revolving credit facility expanded toward $2bn. 2026 ratings are S&P BB−, Fitch BB− and Moody's B1, all stable.

5. The governance reset. Nacho Abia became CEO on 1 April 2024 (the first non-family CEO), and in February 2025 the chair passed from Thomas Glanzmann to independent director Anne-Catherine Berner; family members remain proprietary directors. The balance between the new leadership and residual family/Scranton influence is debated.

Outlook

The qualitative outlook is a deleveraging and normalization story — refinanced maturities, rising ratings and improving profit — set against an unresolved take-private question and a live litigation tail (the SDNY suit and any appeal of the CNMV fine). This is a compliance-sensitive name: the short-seller allegations should be read as contested claims, and the M&A situation as preliminary rather than agreed.

For the retail investor

Grifols is most naturally read alongside other Spanish healthcare and index names, and forum users often compare its saga with those of other closely-watched issuers. See our companion pages on PharmaMar, another Spanish biopharma name, and on Banco Santander and Inditex.

Many retail investors who follow shares like Grifols also diversify part of their attention into digital assets. WEEX is a crypto exchange offering crypto futures and spot markets, with a futures-first range for traders who want leverage and hedging on assets such as Bitcoin and Ether. To be clear: Grifols shares do not trade on WEEX — the equity trades on the BME. WEEX is a separate venue for the crypto side of a diversified watchlist.

Not investment advice

This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All figures are drawn from company and regulator disclosures on the dates indicated and may have changed; litigation and regulatory matters described are ongoing. Investing in equities and in crypto assets carries risk, including the loss of capital. Do your own research and consult a licensed financial adviser before making any decision.